News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Val-083 for unmethylated GBM


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 Very good results, but these are small studies. In the newly diagnosed group, 7 of 15 patients had a complete response. This is with unmethylated MGMT patients which is a much worse group than methylated.  The data on the recurrent GBM is not available but they describe the trial!

It is possible that Val-083 should be used instead of Temodar for MGMT unmethylated patients.  Val-083 is  similar to Temodar - it is a chemotherapy (but IV not oral), but works at a different part of the DNA strand so the MGMT repair enzyme can not undo the damage like it does with Temodar.  (A GMB patient with unmethylated MGMT produces a lot of the repair enzyme, making Temodar almost ineffective).


Posted on: 11/25/2019

Val-083 for unmethylated GBM

There were 2 presentations at SNO last week:

CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: HALF-WAY REPORT

and

 

 PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE GLIOBLASTOMA IN THE RECURRENT AND ADJUVANT SETTING

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740